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The impact of inflammation suppressor pathways on
Alzheimer’s disease (AD) evolution remains poorly
understood. Human genetic evidence suggests
involvement of the cardinal anti-inflammatory cyto-
kine, interleukin-10 (IL10). We crossed the APP/PS1
mouse model of cerebral amyloidosis with a
mouse deficient in Il10 (APP/PS1+Il10/). Quantita-
tive in silico 3D modeling revealed activated Ab
phagocytic microglia in APP/PS1+Il10/ mice that
restricted cerebral amyloidosis. Genome-wide RNA
sequencing of APP/PS1+Il10/ brains showed se-
lective modulation of innate immune genes that drive
neuroinflammation. Il10 deficiency preserved synap-
tic integrity and mitigated cognitive disturbance in
APP/PS1 mice. In vitro knockdown of microglial
Il10-Stat3 signaling endorsedAbphagocytosis, while
exogenous IL-10 had the converse effect. Il10 defi-
ciency also partially overcame inhibition of microglial
Ab uptake by human Apolipoprotein E. Finally, the
IL-10 signaling pathway was abnormally elevated
in AD patient brains. Our results suggest that
‘‘rebalancing’’ innate immunity by blocking the IL-10
anti-inflammatory response may be therapeutically
relevant for AD.
INTRODUCTION
Alzheimer’s disease (AD), the most common form of dementia in
the elderly, is characterized by a triad of pathological features:
extracellular amyloid deposits predominantly composed of am-
yloid-b (Ab) peptides, intracellular neurofibrillary tangles (NFTs)
chiefly comprised of abnormally folded tau protein, and gliosis
consisting of reactive microglia and astrocytes surrounding
b-amyloid plaques. During the past century, intense focus has
been directed toward studying production, aggregation, and
spreading of b-amyloid plaques and subsequent neurodegener-
ation (Mucke and Selkoe, 2012). These studies have led to the
conclusion that AD pathology is driven by an imbalance between
Ab production and clearance.534 Neuron 85, 534–548, February 4, 2015 ª2015 Elsevier Inc.Indeed, autosomal-dominant forms of familial Alzheimer’s dis-
ease (FAD) are principally linked tomutations affecting b-amyloid
precursor protein (b-APP) or Presenilin 1 (PS1) function (De
Strooper et al., 2012), leading to amyloidogenic processing of
b-APP and accumulation of cerebral amyloid deposits. Nonethe-
less, the vast majority of patients have the sporadic form of the
disease, which likely arises from a combination of poorly defined
genetic and environmental risk factors. These factors do not
necessarily affect b-APP proteolysis, and it has instead been
suggested that dysregulated Ab clearance—rather than produc-
tion—is the etiologic driving force in sporadic AD (Mawuenyega
et al., 2010). As the resident macrophages of the CNS, microglia
are chiefly responsible for phagocytosis and clearance of cellular
detritus. Furthermore, numerous studies have validated the abil-
ity of microglia to phagocytose Ab peptides (Grathwohl et al.,
2009; Herber et al., 2004; Wilcock et al., 2004; Wyss-Coray
et al., 2001). However, mounting evidence suggests that micro-
glia are dysfunctional in the AD brain (Lopes et al., 2008; Streit
et al., 2009). While prolonged activation of brain inflammatory
processes coordinated by the cerebral innate immune system
is now accepted as an AD etiologic event (Wyss-Coray and
Mucke, 2002), the role of anti-inflammatory pathways in Ab
clearance and AD pathobiology has been largely overlooked.
Inflammatory responses are kept under control by two key
immunoregulatory cytokines: transforming growth factor-b
(TGF-b) and interleukin-10 (IL-10) (Li and Flavell, 2008; Strle
et al., 2001; Williams et al., 2004; Wyss-Coray and Mucke,
2002). Our laboratory has previously shown that blockade of
anti-inflammatory TGF-b-Smad 2/3 signaling in innate immune
cells mitigates cerebral amyloidosis and behavioral deficits in
the Tg2576 mouse model (Town et al., 2008). These data sug-
gest that the innate immune system can be harnessed to clear
Ab in the context of anti-inflammatory signaling inhibition.
Remarkably, cerebral levels of IL-10 were increased in this sce-
nario, in line with the elevated IL-10 signaling observed in reac-
tive glia neighboring b-amyloid plaques in aged Tg2576 mice
(Apelt and Schliebs, 2001). Also, a functional polymorphism
within the Il10 gene has been linked to increased risk of AD in
some (Arosio et al., 2004; Lio et al., 2003; Ma et al., 2005; Vural
et al., 2009), but not all, populations (Depboylu et al., 2003;
Ramos et al., 2006; Scassellati et al., 2004).
IL-10 signaling induced by binding of IL-10 homodimer to its
cognate receptor (IL-10R) leads to phosphorylation of associated
Janus kinase 1 (Jak1) and downstream phosphorylation and
activation of signal transducer and activator of transcription 3
(STAT3). Phosphorylated STAT3 translocates to the nucleus,
where it regulates transcription of downstream cytokines
and inflammatory genes including SOCS3 (Murray, 2006). To
investigate putative involvement of the IL-10 pathway in AD-like
pathology, we crossed the Tg(APPswe, PS1DE9) mouse model
of cerebral amyloidosis with animals deficient in Il10. Genetic
disruption of Il10 licensed Ab phagocytosis by activated
microglia and reduced Ab load in APP/PS1 mouse brains.
Transcriptome analysis of brains from APP/PS1+Il10/ mice by
RNA sequencing (RNAseq) revealed modulation of the inflamma-
torymilieu, includingselect inflammatoryandmicroglial regulatory
genes. Finally, Il10 deficiency partially rescued synaptic toxicity
and behavioral impairment driven by the APP/PS1 transgenes.
RESULTS
Deficiency in Il10 Mitigates Cerebral Amyloidosis in
APP/PS1 Mice
To assess the role of Il10 in AD-like pathology, we bred Il10/
mice (Ku¨hn et al., 1993) to Tg(APPswe,PSEN1DE9) animals
(referred as APP/PS1 mice in the present study) (Jankowsky
et al., 2001, 2004). APP/PS1+Il10/ and APP/PS1+Il10+/ mice
were born at Mendelian ratios and exhibited no anatomical
defects or premature death compared to APP/PS1+Il10+/+
mice. IL-10 levels measured in the plasma of 12-month-old
mice followed an Il10 allele-dependent expression pattern (pg
of IL-10/ml of plasma: APP/PS1+Il10+/+, 19.0 ± 1.1 [n = 6],
APP/PS1+Il10+/ [n = 4], 10.8 ± 2.1**; APP/PS1+Il10/, 0.20 ±
0.04*** [n = 4]; **p > 0.01, ***p > 0.001 compared to APP/
PS1+Il10+/+ mice by one-way ANOVA and Dunnett’s post hoc
test). At 12 to 13 months of age, APP/PS1+Il10/ mice mani-
fested significantly reduced amyloid deposition in cingulate
cortex (CC), entorhinal cortex (EC), and hippocampus (HC) as
measured by thioflavin S histochemistry (Figures 1A and 1B;
reductions versus APP/PS1+Il10+/+ mice: CC, 74%; EC, 78%;
HC, 67%, ***p < 0.001; by one-way ANOVA and Dunnett’s
post hoc test). Furthermore, 4G8+ b-amyloid plaques were also
significantly reduced in APP/PS1+Il10/ compared to APP/
PS1+Il10+/+ animals (Figure 1C; CC, 67%; EC, 50%; HC, 70%,
*p < 0.05, **p < 0.01, ***p < 0.001; one-way ANOVAandDunnett’s
post hoc test). Ab plaque morphometry was analyzed by blindly
assigning plaques to one of three mutually exclusive categories
based on maximum diameter. Surprisingly, APP/PS1+Il10/
mice had modest but statistically significant increases in abun-
dance of small (<25 mm) plaques in the CC and EC versus APP/
PS1+Il10+/+ animals (Figure S1A, *p < 0.05 by one-way ANOVA
and Fisher’s post hoc test). Yet, numbers of medium- (25–
50 mm) and large-sized (>50 mm) plaques were significantly
reduced by 48%–74% in the CC, and this effect trended toward
significance in the ECandHC (FiguresS1BandS1C, *p<0.05; by
one-way ANOVA and Fisher’s post hoc test). In addition to Ab
plaques in brain parenchyma, 86% of AD patients deposit Ab in
cerebral blood vessels, known as cerebral amyloid angiopathy
(CAA) (Ellis et al., 1996; Kanekiyo et al., 2012). APP/PS1 mice
also develop CAA, and this pathology was significantly reduced
by 46%–68% in EC and HC (and trended toward significance in
CC) inAPP/PS1+Il10/ versusAPP/PS1+Il10+/+mice (Figure 1D,*p < 0.05, **p < 0.01; by one-way ANOVA and Dunnett’s post hoc
test). Interestingly, no evidence for Il10 heterozygous advantage
was found for Ab deposits in brain parenchyma or cerebral ves-
sels (Figures 1A–1D and S1, p > 0.05).
Biochemical analysis revealedstriking reductions inbothAb1–40
and Ab1–42 abundance in brains ofAPP/PS1
+Il10/ compared to
APP/PS1+Il10+/+ mice. In the detergent-soluble fraction, Ab1–40
was reduced by 63% and Ab1–42 by 70% (Figures 1E and 1F,
*p < 0.05, **p < 0.01; by one-way ANOVA and Dunnett’s post
hoc test). Additionally, after re-extraction of the detergent-insol-
uble pellet in the chaotropic agent, guanidine-HCl, Ab1–40 was
lowered by 79% and Ab1–42, by 85% in APP/PS1
+Il10/ versus
APP/PS1+Il10+/+ mice (Figures 1G and 1H, *p < 0.05; by one-
way ANOVA and Dunnett’s post hoc test). Interestingly, deter-
gent-soluble cerebral Ab1–40 and Ab1–42 abundance was
decreased by 35%–42% in APP/PS1+Il10+/ mice, although this
trend did not reach statistical significance (Figures 1E and 1F,
p > 0.05; by one-way ANOVA and Dunnett’s post hoc test).
To rule out the possibility of an effect on cerebral amyloidosis
due to altered APPSwe or PS1DE9 transgene expression, western
blot and quantitative real-time reverse transcriptase PCR (qPCR)
analyses were performed on protein and RNA extracted from
frontal cortex of all three groups of mice. No between-groups
differences were found on PS1 or APP protein or mRNA levels
(Figures 1I–1K). To determine if Il10 deficiency altered APPmeta-
bolism, amyloidogenic C99 fragments were detected in frontal
cortex brain extracts (n = 5 to 6 for each mouse group) by west-
ern blot but remained unmodified (quantitation of C99 band in-
tensity normalized to holo-APP and b-actin: APP/PS1+Il10+/+,
99.5 ± 7.8; APP/PS1+Il10+/, 96.8 ± 7.3; APP/PS1+Il10/,
87.9 ± 5.9, p > 0.05; by one-way ANOVA and Dunnett’s
post hoc test). Finally, to address the possibility of Ab peptide
efflux from brain to blood, we assayed plasma levels of Ab1–40
and Ab1–42 but did not detect significant differences (pg
of Ab1–40/ml of plasma: APP/PS1
+Il10+/+, 594.3 ± 92.8; APP/
PS1+Il10+/, 649.4 ± 90.3; APP/PS1+Il10/, 752.3 ± 55.4; pg
of Ab1–42/mL of plasma: APP/PS1
+Il10+/+, 220.2 ± 60.9; APP/
PS1+Il10+/, 372.8 ± 62.5; APP/PS1+Il10/, 294.4 ± 39.2,
p > 0.05; by one-way ANOVA and Dunnett’s post hoc test).
Il10 Deficiency Activates Innate Immunity in Brains of
APP/PS1 Mice
Within the CNS, IL-10 is mainly produced by astrocytes and mi-
croglia (Ledeboer et al., 2002), the latter being brain-resident
innate immune cells that are centrally positioned to phagocytose
and clear Ab (Aguzzi et al., 2013; Guillot-Sestier and Town,
2013). To confirm the cellular source of cerebral IL-10 in our
experimental animals, Il10 mRNA levels were analyzed by
qPCR in CD11b+ and CD11b cellular fractions isolated from
brain single-cell suspensions (Figure S2A). The CD11b+ cell frac-
tion highly expressed established microglial markers (i.e., Iba1,
Cx3cr1, Csf1r, and Itgb5; Figure S2A) (Butovsky et al., 2014),
while the CD11b cell fraction expressed astrocytic and
neuronal markers (i.e., S100b and Map2). Interestingly, the
CD11b+ fraction was largely enriched in Il10r mRNA compared
to CD11b cells, and Il10r expression was strikingly increased
in microglia from APP/PS1+ animals (Figure S2A). Finally, Il10
mRNA levels were markedly increased in microglia from APP/Neuron 85, 534–548, February 4, 2015 ª2015 Elsevier Inc. 535
Figure 1. Il10 Deficiency Reduces Cerebral Amyloidosis in APP/PS1 Mice
(A) Representative micrographs of amyloid plaques labeled with thioflavin S from the CC, EC, and HC of APP/PS1 mice homozygous, heterozygous, or
completely deficient for Il10. Scale bar denotes 100 mm.
(B and C) Quantitation of thioflavin S (B) and 4G8 (C) labeling.
(D) Semiquantitative analysis of CAA severity (CAA score) from thioflavin S-labeled brain sections.
(E–H) ELISA analysis of frontal cortex detergent-soluble ([E] and [F]) or guanidine-HCl-extracted ([G] and [H]) Ab1–40 and Ab1–42 species from mice with the
indicated genotypes. For (B)–(H), data are presented as mean ± SEM for APP/PS1+Il10+/+ (n = 10–18), APP/PS1+Il10+/ (n = 9–24), and APP/PS1+Il10/ mice
(n = 3–10); *p < 0.05, **p < 0.01, *and **p < 0.001.
(legend continued on next page)
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PS1+Il10+/+ brains, suggesting that IL-10 is produced by CD11b+
microglia and likely participates in autocrine signaling via IL-10R
in brains of APP/PS1+ mice. To investigate the effect of Il10 defi-
ciency on neuroinflammation in response to Ab deposition, cor-
onal sections from 12- to 13-month-old mouse brains were
immunostained for ionized calcium-binding receptor 1 (Iba1)
(Ahmed et al., 2007), and data showed 54%–69% significantly
increased signal in APP/PS1+Il10/ versus APP/PS1+Il10+/+
mice (Figure 2A, *p < 0.05, **p < 0.01; by one-way ANOVA and
Dunnett’s post hoc test). Interestingly, in non-transgenic ani-
mals, Il10 deficiency did not modify Iba1+ immunoreactivity (%
of labeled area: CC: Il10+/+, 1.35 ± 0.16; Il10/, 1.58 ± 0.19;
EC: Il10+/+, 1.03 ± 0.15; Il10/, 1.44 ± 0.16; HC: Il10+/+, 2.30 ±
0.43; Il10/, 2.06 ± 0.23; n = 6 per genotype, by t test), indicating
that Il10 deficiency selectively modified microglial phenotype in
the context of the APP/PS1 transgenes. A similar pattern of sta-
tistically significant results (from 55%–64%) was observed for
glial fibrillary acidic protein (GFAP)-reactive astrocytes in EC
and HC (Figures 2B and 2C, *p < 0.05, ***p < 0.001; by one-
way ANOVA and Dunnett’s post hoc test). Remarkably, APP/
PS1+Il10/ mice that still had remaining b-amyloid plaques
demonstrated statistically significant 74%–143% increased
CD11b+-activated microglial burden (Townsend et al., 2005) in
close vicinity of Ab deposits in the CC, EC, and HC (Figures 2C
and 2D, *p < 0.05, **p < 0.01; by one-way ANOVA and Dunnett’s
post hoc test). Further evidence of 59%–266% significantly
increased microglial activation in APP/PS1+Il10/ mice came
from CD45 immunostaining data (Figure 2E, *p < 0.05, ***p <
0.001; by one-way ANOVA and Dunnett’s post hoc test) (Tan
et al., 2000; Zhu et al., 2011). We did not observe histologic ev-
idence of vascular cuffing or presence of round, non-process-
bearing CD45 highly expressing (CD45hi) mononuclear cells
(Town et al., 2008), and flow cytometric analysis of single-cell
suspensions isolated from APP/PS1+Il10+/+ versus APP/PS1+-
Il10/ brains showed no differences on abundance of CD45hi
or intermediate-expressing (CD45int) populations (Figure S2B).
Interestingly, amyloid plaques in APP/PS1+Il10/ mice ap-
peared more diffuse than typical dense-cored plaques present
in APP/PS1+Il10+/+ mice, and were accompanied by 50%–
74% increased activated CD68+ microglia (Figures 2F and 2G,
*p < 0.05; by one-way ANOVA and Dunnett’s post hoc test). In
addition, association of microglia with amyloid deposits was
significantly enhanced by 34% in APP/PS1+Il10/ brains
compared to APP/PS1+Il10+/+ littermates (p < 0,001; by t test).
Modified Neuroinflammatory Profile in APP/PS1 Mice
Deficient for Il10
To assess global transcriptional changes in brains of APP/PS1
mice deficient in Il10, RNAseq was performed. Total brain
mRNA was isolated from 12-month-old APP/PS1+: Il10+/+,
Il10+/, or Il10/ animals (n = 5 per group). Clustering of individ-(I) Western blots of human (h) APP or hPS1 levels in frontal cortex homogenates
control.
(J) Quantitation of hAPP or hPS1 protein levels in frontal cortex homogenates from
b-actin. Data are represented as mean ± SEM for n = 6 samples for each group,
(K) qPCR analysis of APP and PS1 mRNA levels in frontal cortex from mice with t
represented as mean ± SEM for n = 6 per group; non-significant. See also Figurual animal expression profiles resulted in segregation of the
two homozygous populations, with heterozygous animals inter-
mixed (Figure S3). Comparative expression of 14,800 detected
RefSeq genes (normalized as RPKM; average per genotype) re-
vealed expression changes that were Il10 allele dependent (Fig-
ure 3A). Most genes remained unchanged in APP/PS1+Il10/
versus APP/PS1+Il10+/+ mice, with only 117 genes having
greater than 2-fold differences. Cluster analysis of those 117
genes was performed, resulting in three distinct patterns: A,
B, and C (Figure 3B). We further defined these groups as A1,
A2, B, and C, where group A1 and A2 genes were decreased
in APP/PS1+Il10/ mice and APP/PS1+Il10+/ mice had an in-
termediate result; group B genes were only decreased in APP/
PS1+Il10/ mice, and group C genes were increased in APP/
PS1+Il10/ mice. When these genes were further interrogated
for immune-related function(s), the majority of immune genes
fell into groups A1 and A2 (Figure 3B). These genes, corre-
sponding fold changes with associated statistical significance
levels, and global function(s) in immune responses are pre-
sented in Figure 3C. Interestingly, expression of Apoe (a well-
established genetic risk factor for late-onset AD) was reduced
in APP/PS1+Il10/ compared to APP/PS1+Il10+/+ animals, vali-
dating microglial qPCR data (see Figure S2A). In general, im-
mune genes with altered expression profiles were responsible
for innate immune cell regulation, chemoattraction, Ab interac-
tion, and phagocytosis.
IL-10 Retards while Il10 Deficiency Promotes Microglial
Ab Phagocytosis
Data described above suggested that Il10 deficiency endorsed a
beneficial form of innate immune activation that favored micro-
glial b-amyloid clearance. To directly investigate the effects of
IL-10 on microglial Ab phagocytosis, primary cultures of micro-
glia were established from Il10+/+ or Il10/ mice, and Ab1-42
phagocytosis was evaluated. Remarkably, ELISA measurement
of Ab1–42 intracellular content showed recombinant IL-10 treat-
ment to significantly decrease preaggregated Ab1–42 uptake by
41% in Il10+/+ and 62% in Il10/ mouse primary microglia (Fig-
ure 4A, Il10+/+, yp = 0.06 and Il10/, ***p < 0.001; by one-way
ANOVA and Sidak’s post hoc test), and a similar pattern of re-
sults was observed in a rat microglial cell line (data not shown).
Treatment with recombinant IL-10 also (1) reduced phagolyso-
somal CD68 labeling by 49% (Figures S4A and S4B, *p < 0.05;
by t test), (2) diminished intracellular Ab1–42-cy3 signal by 46%
(Figure S4C, *p < 0.05; by t test), and (3) induced STAT3 translo-
cation to the nucleus (Figures S4D and S4E, **p < 0.01; by t test).
These data show that IL-10 treatment shifts microglial activation
away from Ab phagocytosis via increasing activation of STAT3.
In a reciprocal set of experiments, Ab1–42 uptake was
increased by 60% in Il10/ primary microglia (Figure 4A,
Il10+/+ versus Il10/, *p < 0.05; by one-way ANOVA and Sidak’sof APP/PS1 mice with the indicated genotypes. b-actin is shown as a loading
APP/PS1mice of the indicated genotypes. Expression levels are normalized to
with APP/PS1+Il10+/+ signal normalized to 100%; non-significant.
he indicated genotypes. The mRNA levels are normalized to Hprt, and data are
e S1.
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Figure 2. Il10 Deficient APP/PS1 Mice Acti-
vate Cerebral Innate Immunity
(A–F) Microgliosis and astrogliosis were quantified
in coronal sections labeled with Iba1 (A), GFAP (B),
CD11b (D), CD45 (E), or CD68 (F) antibodies in
mice with the indicated genotypes. Data are rep-
resented as mean ± SEM for APP/PS1+Il10+/+
(n = 8–13), APP/PS1+Il10+/ (n = 8–16), and APP/
PS1+Il10/ mice (n = 3–10); *p < 0.05, **p < 0.01,
and ***p < 0.001.
(C) Representative micrographs of CC, EC, and
HC from APP/PS1 mice homozygous, heterozy-
gous, or completely deficient for Il10. Amyloid
plaques were labeled using 4G8 antibody, and
CD11b+microglia or GFAP+ astrocytes were found
associated with b-amyloid deposits. Scale bar
denotes 50 mm.
(G) Representative microphotographs are shown
of b-amyloid plaque morphology in cortex of APP/
PS1+Il10/ versus APP/PS1+Il10+/+ mice. Amy-
loid plaques are labeled with thioflavin S while
phagocytic microglia are marked by CD68 anti-
body. White arrows represent CD68+ cells colo-
calized with amyloid deposits. Scale bar denotes
20 mm. See also Figure S2.post hoc test). To determine if Stat3 knockdown could pheno-
copy the effect of Il10 deletion on microglial Ab phagocytosis,
we used amousemicroglial cell line (N9) that responded similarly
to mouse primary microglia in terms of IL-10-dependent reduc-
tion of Ab phagocytosis (Figure S4F, *p < 0.05; by t test). Three
independent Stat3 knockdown microglial N9 lines were gener-
ated via shStat3 lentiviral infection, and STAT3 expression was538 Neuron 85, 534–548, February 4, 2015 ª2015 Elsevier Inc.validated by immunocytochemistry and
western blot (Figures S4G and S4H).
Strikingly, reduced STAT3 nuclear trans-
location occurred with increased Ab1–42-
cy3 within CD68+ lysosomes (Figure S4I)
in the same manner as Il10 deletion.
To further investigate this effect,
morphology and Ab phagocytic aptitude
of Il10+/+ versus Il10/ primary microglia
were evaluated by live cell imaging.
Twenty-four hours after transfection with
a Lamp1-GFP construct, cells were chal-
lenged with Ab1–42-cy3 to follow Ab1–42
uptake into Lamp1+ phagolysosomes.
Representative images from Movies S1
and S2 are shown in Figure 4B. Interest-
ingly, Ab1–42-cy3 was encapsulated
within Lamp1+ structures in both Il10+/+
and Il10/ microglia; however, Ab-con-
taining phagolysosomes were enlarged
in Il10/ microglia (Figure 4B; see white
arrows and Movies S1 and S2).
Strikingly, a similar patternof resultswas
observed in vivo. APP/PS1+ mice pre-
sented Iba1+ microglia containing 4G8+
Ab encapsulated within Lamp1+ (Figures4C and 4D) and CD68+ (Figure S4J) phagolysosomes. Yet, APP/
PS1+Il10/ brains had demonstrably increased abundance of
Iba1+ microglia that costained for Lamp1+ lysosomes and for
4G8+Ab (Figures4Cand4D). Importantly, phagolysosomeswithin
Iba1+cellswere increasedby92%in thecortexand140% inHCof
APP/PS1+Il10/ versus APP/PS1+Il10+/+ mice (Figure 4E, *p <
0.05, **p < 0.01; by t test). Analysis of plaque-associatedmicroglia
Figure 3. TranscriptomeAnalysis of Brains fromAPP/PS1MiceDefi-
cient in Il10
(A) Scatterplot of the average expression per gene (RPKM) of APP/PS1+Il10+/+
(n = 5) plotted against APP/PS1+Il10+/ (n = 5) or APP/PS1+Il10/mice (n = 5).
The blue line represents a 2-fold change.
(B) A heatmap of k means cluster analysis of log2-transformed expression
(RPKM) is shown for 117 genes with 2-fold or greater change. Genes that are
immune related (as reported by the KEGG database) are indicated in orange.
(C) A table of immune- and inflammation-related genes identified from the
heatmap with log2 (fold change) of APP/PS1
+Il10+/+ versus APP/PS1+Il10/
mice is shown, and false discovery rate is calculated by the edgeR package in
Bioconductor. See also Figure S3.revealed an increased proportion of cells containing phagolyso-
some-encapsulated amyloid in Il10-deficient animals (Figure 4F;
cortex, 62%; HC, 60%, ***p < 0.001; by t test). Finally, the totalamount of 4G8+ Ab loaded within Lamp1+ phagolysosomes
was significantly augmented in APP/PS1+Il10/ versus APP/
PS1+Il10+/+ brains (Figure 4G; cortex, 148%; HC, 110%, *p <
0.05, **p < 0.01; by t test). Altogether, our results demonstrate
that Il10 deficiency enhances microglial amyloid phagocytic
function in APP/PS1mice.
We previously observed by brain RNAseq (Figure 3) and mi-
croglial qPCR (Figure S2A) that Apoe expression was reduced
in APP/PS1+Il10/mice. To determine if human ApoE isoforms
(E2, E3, and E4) acted as molecular chaperones to bind Ab and
altermicroglial phagocytosis, we preincubated Cy3-labeled (Fig-
ure 4H) or unlabeled (Figure 4I) human recombinant Ab1–42 with
human recombinant ApoE2, ApoE3, or ApoE4. Il10+/+ and
Il10/ primary microglial cultures were then treated with this
mixture. Human ApoE drastically reduced Ab uptake by micro-
glia in an isoform-specific manner (E4>E3>E2), mirroring the
well-established ApoE-human AD risk relationship (Figure 4H).
This was confirmed by ELISA quantitation of Ab uptake in a par-
allel set of experiments using unlabeled Ab (Figure 4I, **p < 0.01,
***p < 0.001; by one-way ANOVA and post hoc t test). Strikingly,
human ApoE isoform-dependent reduction of microglial Ab
phagocytosis was significantly rescued by Il10 deficiency in
the case of ApoE3.
Il10 Deficiency Preserves Synaptic Integrity in APP/PS1
Mice
A key challenge for immunomodulatory strategies that promote
cerebral amyloid clearance is avoidance of bystander neuronal
injury due to neuroinflammation (Guillot-Sestier and Town,
2013; Town et al., 2005). To determine whether synaptic health
was impacted by Il10 deficiency in APP/PS1 mice, coronal
brain sections from 12-month-old mice were stained with an
antibody directed against synaptophysin. As predicted, synap-
tophysin puncta density was reduced by 37%–40% in APP/
PS1+Il10+/+ versus APP/PS1Il10+/+ littermates, both in HC
and in cerebral cortex (Figures 5A–5C; *p < 0.05, **p < 0.01,
by one-way ANOVA and Dunnett’s post hoc test). Strikingly,
however, APP/PS1+Il10/ mice had hippocampal and cortical
synaptophysin labeling density that was restored to that of
APP/PS1 littermates (Figures 5A–5C). Western blot analysis
of cortical protein extracts confirmed our immunohistochemical
observations (Figure 5D), and densitometric analysis disclosed
reduced synaptophysin abundance in brains of APP/
PS1+Il10+/+ and APP/PS1+Il10+/ mice compared to non-trans-
genic controls (APP/PS1-Il10+/+, n = 6, normalized to 1 versus
APP/PS1+Il10+/+, 0.52 ± 0.20*, n = 6; and APP/PS1Il10+/,
1.07 ± 0.33, n = 6 versus APP/PS1+Il10+/, 0.65 ± 0.33*, n =
8; *p < 0.05 by one-way ANOVA and Sidak’s post hoc test).
Remarkably, Il10 deficiency in APP/PS1+ mice normalized
synaptophysin abundance to non-transgenic animals (APP/
PS1+Il10/, 0.72 ± 0.12, n = 5 versus APP/PS1-Il10/,
0.97 ± 0.30, n = 3; not significantly different by one-way
ANOVA and Sidak’s post hoc test). The beneficial effect of
Il10 loss on synaptophysin abundance was APP/PS1 transgene
dependent, because synaptophysin levels were not affected
in Il10 heterozygotes or Il10-deficient mice that lacked the
APP/PS1 transgenes (Figure 5D; p > 0.05, by one-way
ANOVA and Dunnett’s post hoc test).Neuron 85, 534–548, February 4, 2015 ª2015 Elsevier Inc. 539
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Figure 4. Il10 Deficiency Increases Microglial b-Amyloid Phagocytosis
(A) ELISA analysis of Ab1–42 intracellular content in cultured Il10
+/+ or Il10/mouse primarymicroglia. Cultures were treated for 2 hr with recombinant IL-10 before
challenge with human synthetic Ab1–42 microaggregates for 6 hr. Data are presented as mean ± SEM of four independent experiments carried out in duplicate;
yp = 0.06, *p < 0.05, and ***p < 0.001.
(B) Representative microphotographs of Lamp1-GFP-transfected primary cultures of microglia (Il10+/+ or Il10/) challenged with Ab1–42-cy3 microaggregates.
White arrows designate enlarged Lamp1+ phagolysosomes containing Ab1–42-cy3 in Il10
/ microglia.
(legend continued on next page)
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Deficiency in Il10 Mitigates APP/PS1 Transgene-
Associated Behavioral Impairment
To evaluate functional consequences of preserved synaptic
health in APP/PS1+Il10/ mice, all six groups of littermates
were cognitively evaluated. Prior to behavioral testing, mice
were subjected to neurological screening to assess auditory, vi-
sual, and olfactory acuity and response to a tactile stimulus.
Additionally, coordination, balance, and grip strength were
tested. Mice performed equally well for each of the neurological
screening tests (data not shown), and so all animals were
included in subsequent behavioral assays. Locomotion and
spontaneous activity were tested in an open field. Yet, no signif-
icant differences between any of the six groups were observed
when considering rearing or time spent in the center of the field
(Figure S5A), indicating that subsequent behavioral results were
not distorted by variation in anxiety between genotypes. Howev-
er, when considering fine movements (i.e., grooming, explora-
tion on four limbs, and sniffing) and total activity, APP/
PS1+Il10+/+ mice were hyperactive versus controls, a behavioral
phenotype that may result from cortical and hippocampal injury
leading to disinhibition (Town et al., 2008). Strikingly, APP/PS1+-
Il10/mice had complete mitigation of hyperactivity (Figures 6A
and S5A; y p < 0.1, *p < 0.05, ****p < 0.0001; by one-way ANOVA
and Fisher’s LSD post hoc test).
Next, learning and episodic memory were assessed in the
novel object recognition test, which is dependent on hippocam-
pal and cortical function (Hammond et al., 2004). If mice
remember a previously encountered object compared to a novel
object, they tend to preferentially explore the new object more
than the familiar one. As expected, after a 1 hr retention period,
APP/PS1+Il10+/+ mice trended toward lower preference for the
novel object than controls (Figure 6B; y p = 0.07; by one-way
ANOVA and Fisher’s LSD post hoc test). Strikingly, defective
novel object recognition was completely remediated by Il10
deficiency, and partial amelioration of this behavioral defect
was observed in APP/PS1+Il10+/ mice (Figure 6B). A similar
trend of results occurred after 24 hr of retention (Figure S5B).
Importantly, neither short-term (1 hr) nor long-term (24 hr) novel
object memory were affected by Il10 deficiency in non-
transgenic controls (Figure 6B and Figure S5B; p > 0.05, by
one-way ANOVA and Fisher’s LSD or Sidak’s post hoc tests,
respectively).
Spatial working memory was evaluated by spontaneous
alternation in the Y-maze (Deacon et al., 2002). Similar to
the open-field test, APP/PS1+Il10+/+ mice were hyperactive
compared to control littermates, as operationalized by total(C) Representativemicrophotographs of amyloid deposits in cortex ofAPP/PS1+Il
microglia, with Iba1 and Lamp1.
(D) 3D reconstruction from confocal image stacks showing 4G8+ Ab encapsu
PS1+Il10/ versus APP/PS1+Il10+/+ mice. Blue arrows indicate rotation of insets
(E–G) Quantitation of microglial volume occupied by Lamp1+ phagolysosomes (E)
4G8+ amyloid encapsulated in phagolysosomes (G) in the EC and HC of mice w
PS1+Il10+/+ (n = 4) or APP/PS1+Il10/ (n = 5) mice; *p < 0.05, **p < 0.01, ***p <
(H) Representative microphotographs of Iba1+ primary cultures of microglia (Il10
human recombinant ApoE2, ApoE3, or ApoE4.
(I) ELISA analysis of Ab1–42 intracellular content in cultured mouse primary micro
preaggregated in presence of recombinant ApoE2, ApoE3, or ApoE4. Data are
duplicate; **p < 0.01; ***p < 0.001. See also Figure S4 and Movies S1 and S2.number of arm entries. Again, this behavioral phenotype was
completely mitigated by Il10 deficiency (Figure 6C, *p % 0.05;
by one-way ANOVA and Fisher’s LSD post hoc test). As
expected, APP/PS1+Il10+/+ mouse percentage spontaneous
alternation trended toward less frequent than controls, and
Il10 deficiency did not modify this effect (Figure 6D, y p =
0.07; by one-way ANOVA and Fisher’s LSD post hoc test).
As an important control, deficiency in Il10 did not alter sponta-
neous alternation in control littermates lacking the APP/PS1
transgene (Figure 6D, p > 0.05; by one-way ANOVA and
Fisher’s LSD post hoc test).
Finally, mice were tested for HC-dependent spatial refer-
ence learning and memory in the Barnes maze (O’Leary and
Brown, 2009). During the training phase, all of the mouse
groups demonstrated reduced latency to escape with succes-
sive acquisition trials, with the exception of APP/PS1+Il10/
mice, which completed training in two distinct phases. During
the six first trials, acquisition of the escape hole location was
faster than the other groups, but APP/PS1+Il10/ mice spent
more time searching the escape box during the rest of the
training (Figure S5C, *p < 0.05; by one-way ANOVA and
Fisher’s LSD post hoc test). In the probe trial, latency to
escape the maze was increased in APP/PS1+Il10+/+ mice
compared to non-transgenic controls. However, complete
Il10 deficiency did not significantly restore APP/PS1 behav-
ioral deficit in this task. Surprisingly though, APP/PS1+Il10+/
mice performed significantly better than APP/PS1+Il10+/+ ani-
mals in the probe trial (Figure S5D, *p < 0.05; by one-way
ANOVA and Fisher’s LSD post hoc test). During the reversal
phase of the test, no differences in acquisition of the new
escape box location were observed between the six groups
(Figure S5E, p < 0.05; by one-way ANOVA and Fisher’s LSD
post hoc test). No statistically significant gender differences
were found for any of the behavioral paradigms, and so males
and females were considered together in all behavioral
analyses.
IL-10 Signaling Is Elevated in AD Patient Brains
Finally, we sought to evaluate IL-10 signaling in postmortem
samples from AD patient brains versus age-matched, non-
demented controls. Hippocampal sections were stained for IL-
10 receptor alpha chain (IL-10Ra) and microtubule-associated
protein 2 (MAP2, a neuronal marker). Interestingly, IL10Ra
expression was elevated in AD compared to control brains,
and some of these signals could be found colocalized with
MAP2+ neurons (Figures 7A, see white arrowheads, and 7B;10/ versusAPP/PS1+Il10+/+ mice. Amyloid deposits are labeled with 4G8 and
lated within Lamp1+ structures in Iba1+ microglia present in brains of APP/
in the Z-plane to show presence of Ab within phagolysosomes.
, percent of Iba1+ microglia containing amyloid-loaded phagolysosomes (F), or
ith the indicated genotypes. Data are represented as mean ± SEM for APP/
0.001.
+/+ or Il10/) challenged with Ab1-42-cy3 microaggregates preincubated with
glia (Il10+/+ or Il10/). Cells were treated for 6 hr with human synthetic Ab1–42
presented as mean ± SEM of two independent experiments carried out in
Neuron 85, 534–548, February 4, 2015 ª2015 Elsevier Inc. 541
Figure 5. Preservation of Synaptic Integrity in Il10 Deficient APP/PS1 Mice
(A and B) Representative microphotographs of synaptophysin labeling in HC (A) or cortex (B) of mice with the indicated genotypes. Lower panels are 3.53 higher
magnification of the upper images. Scale bars denote (a) 87 mm or (b) 25 mm.
(C) Quantitation of synaptophysin labeling in HC and cortex is shown as mean ± SEM (n = 4 per group); *p < 0.05; **p < 0.01.
(D) Western blot of synaptophysin levels in frontal cortex homogenates of mice with the indicated genotypes. b-actin served as a loading control.**p < 0.01; by student’s t test). Furthermore, phospho-Jak1, a
key downstream effector kinase of the IL-10 pathway, was
elevated in AD brains in close proximity to thioflavin S+ amyloid
plaques (Figures 7C and 7D, *p < 0.05; by student’s t test). West-
ern blot analyses of hippocampal protein extracts from a sepa-
rate cohort confirmed our immunohistochemical observations,
with densitometry disclosing increases of 6.5-fold in IL10Ra (Fig-
ure 7E, *p < 0.05), 2.3-fold in Jak1 (Figure 7F, yp = 0.09), 2.6-fold
in phospho-Jak1 (Figure 7G, *p < 0.05), 4.2-fold in STAT3 (Fig-
ure 7H, *p < 0.05), 1.6-fold in phospho-STAT3 (Figure 7I, yp =
0.1), and 1.9-fold in SOCS3 (Figure 7J, yp = 0.07) abundance
(all by student’s t test). Taken together, these data indicate
elevated IL-10 signaling in AD patient versus age-matched con-
trol brains. Interestingly, we also observed increased Il10 and542 Neuron 85, 534–548, February 4, 2015 ª2015 Elsevier Inc.Il10r mRNA levels in microglia isolated from brains of APP/
PS1+ mice (Figure S2A).
DISCUSSION
While once regarded as epiphenomenon, the impact of the cere-
bral innate immune response on AD pathology has become a
topic of intense interest (Gandy andHeppner, 2013; Guillot-Sest-
ier and Town, 2013; Weitz and Town, 2012). This has prompted
the need for a deeper understanding of which innate immune
pathways are deregulated in the context of the disease. While
proinflammatory cytokines have received attention in this regard,
the concept that dysregulated anti-inflammatory cytokines may
be deleterious in AD has been largely overlooked. While several
Figure 6. Il10 Deficiency Partially Restores Cognitive Function in
APP/PS1 Mice
(A) Spontaneous activity was tested in the open field over a 30min period. Bars
represent fine movements of the mice.
(B) Evaluation of episodic memory in the novel object recognition test after 1 hr
of retention. Plots represent the recognition index.
(C and D) Determination of spontaneous alternation in the Y-maze. Bars
represent number of arms entered (C) or percent spontaneous alternation (D).
Data are represented as mean ± SEM for Il10+/+ (n = 5 to 6), Il10+/ (n = 15 to
16), Il10/ (n = 8–11),APP/PS1+Il10+/+ (n = 8–10),APP/PS1+Il10+/ (n = 8 to 9),
and APP/PS1+Il10/ mice (n = 7) compared to APP/PS1 groups; yp% 0.1,
*p% 0.05, and ****p < 0.0001. See also Figure S5.studies have shown that Il10 polymorphism is associated with
late onset AD (Arosio et al., 2004; Lio et al., 2003; Ma et al.,
2005; Vural et al., 2009), almost nothing is known regarding the
putative role of IL-10 in evolution of disease pathology.
To address this knowledge gap, we generated APP/PS1mice
deficient for Il10 and evaluated AD-like pathology and cognitive
impairment. Results showed strikingly reduced cerebral amyloid
pathology in these animals, and remaining plaques were asso-
ciated with activated microglia. Interestingly, plaques in APP/
PS1+Il10/ mice had a ‘‘moth-eaten’’ morphology, similar to
observations made in brains of AD patients or APP transgenic
mice after Ab1-42 immunization (Bard et al., 2000; Nicoll et al.,
2003, 2006; Schenk et al., 1999; Zotova et al., 2011). Importantly,
CD68+ phagocytic microglial cells were observed invading
moth-eaten plaques in APP/PS1+Il10/ brains. Recently,
Krabbe and colleagues showed thatmicroglial cells fail to reduce
Ab burden in transgenic mouse models of AD due to impaired
mobility and phagocytic capacity (Krabbe et al., 2013). Microglial‘‘paralysis’’ may be owed to increasing Ab burden with disease
progression, as shown by others in vitro and in vivo (Korotzer
et al., 1993; Krabbe et al., 2013; Michelucci et al., 2009). Alterna-
tively, it has been hypothesized that microglial senescence in the
aging brain could be responsible for reduced capacity of these
cells to clear cerebral amyloid (Lopes et al., 2008; Miller and
Streit, 2007; Streit et al., 2009). The results we report here
show that stimulation of microglia by recombinant IL-10 induces
nuclear translocation of the downstream signal transducer
STAT3 and reduces Ab phagocytosis, whereas Il10 deficiency
or Stat3 knockdown increases Ab uptake by cultured microglia.
Additionally, Il10 deficiency increases microglial activation and
promotes Ab uptake into Lamp1+ and CD68+ phagolysosomes
in vivo. In this regard, Il10 deficiency in APP/PS1 mice seems
to restore physiologic ability to phagocytose Ab. These findings
dovetail with previous studies from our laboratory and others,
showing that induction of a proinflammatory activation state
endorses cerebral amyloid clearance (Chakrabarty et al.,
2010a, 2010b, 2011; Shaftel et al., 2007; Town et al., 2008).
We did not observe histological evidence of brain-infiltrating
peripheral mononuclear phagocytes in APP/PS1+Il10/ mice
(i.e., vascular cuffing or presence of round, non-process-bearing
leukocytes) as we previously reported in a different innate im-
mune paradigm (Town et al., 2008). Furthermore, Il10 deficiency
did not modify abundance of CD45hi or CD45int mononu-
clear phagocytes in APP/PS1+Il10+/+ versus APP/PS1+Il10/
brains, suggesting that brain-resident microglia are likely thema-
jor population responsible for amyloid clearance. However,
direct experiments aimed at firmly delineating the role of periph-
eral versus central phagocytes in clearance of Ab are warranted.
The study of global transcriptome changes in brains of APP/
PS1mice via RNAseq demonstrates that Il10 deficiencymodifies
cerebral innate immunity. During the analysis, we considered
classical markers for M2-like (TGF-b, Ym-1, and Fizz) and M1-
like (TNF-a, IL-1b, and IL-6) innate immune activation states.
However, we did not detect differential expression of these tar-
gets. Yet, Clec7a expression was strongly decreased in APP/
PS1+Il10/ mice, suggesting polarization of microglial activa-
tion away from the M2 state. Depending on the type of stimula-
tion, microglia demonstrate remarkable plasticity and often
respond with a mixed activation phenotype (Ghassabeh et al.,
2006; Town et al., 2005); therefore, we have previously sug-
gested that M1 or M2 define boundaries of a more broad micro-
glial activation continuum (Town et al., 2005). Nonetheless, our
data reveal global changes in genes that regulate innate immune
activation, inflammation, and phagocytosis. Interestingly, genes
upregulated in brains of patients with late onset AD such as
Tyrobp, Trem2, and C4b (Brouwers et al., 2012; McGeer et al.,
1989; Zhang et al., 2013) were decreased in brains of Il10-defi-
cient APP/PS1 mice. Along similar lines, previous studies have
shown that TLR2 and C4b bind Ab and trigger microglial activa-
tion (Richard et al., 2008) and Ab fibril formation (Sjo¨lander et al.,
2012; Trouw et al., 2008), and APP/PS1+Il10/ brains had
decreased expression of both genes. Strikingly, Chakrabarty
and coworkers have demonstrated that adeno-associated viral
expression of Il10 in brains of APP transgenic mice leads to
age-dependent upregulation of Cxcl10, Tlr2, C4b, and C3ar1
transcripts (Chakrabarty et al., 2015). These global geneNeuron 85, 534–548, February 4, 2015 ª2015 Elsevier Inc. 543
Figure 7. IL-10 Signaling Is Elevated in AD
Patient Brains
(A) Representative microphotographs of IL10Ra
(red) and MAP-2 (green) labeling in hippocampal
sections of AD patients and age-matched, non-
demented control subjects.
(B) Quantitation of IL10Ra immunoreactivity in AD
(n = 6) and control (n = 3) brain sections; data are
presented as mean ± SEM of labeled area for three
optical sections per subject; **p < 0.01.
(C) Representative microphotographs of thioflavin
S+ amyloid plaques (green), MAP-2 (blue), and
phospho-Jak1 (pJak1, red) signals in hippocampal
sections of AD patients and age-matched, non-
demented controls.
(D) Quantitation of pJak1 levels in AD (n = 6) and
control (n = 3) brain sections; data are presented as
mean ± SEM of labeled area for 3 optical sections
per subject; *p < 0.05.
(E–J) Quantification and representative western
blots of IL10Ra (E), Jak1 (F), pJak1 (G), STAT3
(H), pSTAT3 (I), and SOCS3 (J) in hippocampal
homogenates of AD patients and age-matched,
non-demented controls. Expression levels are
normalized to b-tubulin. Data are represented as
mean ± SEM for controls (n = 6) and AD (n = 8)
patients; yp < 0.1; *p < 0.05.expression results corroborate our data showing that Il10 defi-
ciency restores microglial functionality that is compromised in
APP/PS1 transgenic mice. Of particular interest, Apoe expres-
sion was reduced in APP/PS1+Il10/ mice as shown by brain
RNAseq (log2FC = 0.6, FDR = 4 3 105) and by microglial
qPCR. In vitro, recombinant human ApoE3 and ApoE4 drasti-
cally impaired Ab uptake by microglia, while ApoE2 had no
effect, mirroring the well-established ApoE-human AD risk rela-
tionship. Strikingly, Il10 deficiency partially rescued human
ApoE3-associated reduction of Ab uptake compared to Il10+/+
microglia, but was unable to recover the deleterious effect of
human ApoE4. Again, this tracks well with ApoE4 increased
risk for human AD.544 Neuron 85, 534–548, February 4, 2015 ª2015 Elsevier Inc.But does remodeling of cerebral amy-
loid in APP/PS1+Il10/ mice come at
the cost of bystander injury to neurons?
This question is especially pertinent
because we and others have shown that
gliosis can potentially be toxic to neurons
in the context of AD (Maezawa et al.,
2011; Meda et al., 1995; Tan et al.,
1999). Given changes in immune gene
expression profile associated with Il10
deficiency and mitigation of cerebral am-
yloid load, we examined synaptic health
in APP/PS1+Il10/ animals. Synapto-
physin density was reduced in HC and
cortex of APP/PS1 mice compared to
non-transgenic controls, as reported in
transgenic mouse models of cerebral
amyloidosis and in AD patients (Buttiniet al., 2005; Imbimbo et al., 2010; Tampellini et al., 2010; Ubhi
et al., 2010). Interestingly, synaptophysin loss in APP/PS1 mice
was almost completely restored by Il10 deficiency, indicating
that innate immune activation associated with amyloid clearance
in APP/PS1+Il10/ mice preserved synaptic integrity.
Behavioral analyses were performed to determine whether
maintenance of synaptic health in APP/PS1+Il10/ mice trans-
lated to better cognitive function. Importantly, in non-transgenic
control groups, Il10 deficiency did not alter anxiety, learning, or
memory. On the other hand, APP/PS1 mice were hyperactive,
likely resulting from disinhibition associated with hippocampal
or cortical damage (Hsiao et al., 1996; Town et al., 2008).
Additionally, novel object recognition and spatial working
memory were defective in APP/PS1mice, as previously reported
(Hooijmans et al., 2009; O’Leary and Brown, 2009; Webster
et al., 2013). Most importantly, Il10 deficiency mitigated APP/
PS1 transgene-associated hyperactivity in both the open-field
and Y-maze tasks, and both short- and long-term novel object
recognition were completely restored. However, spatial memory
deficits were not rescued in APP/PS1+Il10/ mice, although
spatial reference memory was completely mitigated in APP/
PS1+Il10+/ animals. This latter finding is significant because
eventual clinical therapeutic targeting of IL-10 would likely never
achieve 100% inhibition. These results indicate that Il10 defi-
ciency mitigates a subset of defective cognitive function in
APP/PS1 mice.
To address the possibility that we were simply studying iatro-
genic events not related to human AD, we investigated IL-10
signaling in AD patients versus cognitively healthy, age-matched
controls. Data showed that expression of the cognate IL-10 re-
ceptor, IL10Ra, was elevated in AD patient brains compared to
age-matched, non-demented individuals. Phosphorylated (acti-
vated) Jak1 was correspondingly increased in cells surrounding
amyloid plaques in AD specimens, and protein levels of IL-
10 receptor and downstream effectors were elevated in AD
hippocampal homogenates. Collectively, these results indicate
abnormally increased IL-10 signaling in AD patient brains. These
results corroborate and extend the observations of other groups
that reported increased levels of IL-10 in serum and brain ex-
tracts from AD patients (Angelopoulos et al., 2008; Culpan
et al., 2006; Loewenbrueck et al., 2010). Furthermore, we noted
that Il10 aswell as IL10rmRNA levels were increased inmicroglia
extracted from APP/PS1+Il10+/+ mouse brains, suggesting an
autocrine signaling mechanism associated with increased cere-
bral amyloidosis, a finding that is in line with the IL-10 immuno-
reactive cells observed in close vicinity to b-amyloid deposits
in 13-month-old Tg2576 mice (Apelt and Schliebs, 2001). Since
we show that recombinant IL-10 treatment inhibits Ab uptake
by cultured microglia, elevated IL-10 signaling in AD patient
brains and APP/PS1+ mice may hinder the physiological ability
of microglia to phagocytose and clear cerebral amyloid.
Altogether, our findings show that genetic blockade of Il10pro-
motes a beneficial form of cerebral innate immunity. Il10
blockade enables cerebral Ab clearance via two independent
mechanisms: (1) reducing IL-10/STAT3 signaling to enhance
microglial phagocytic activity and (2) decreasing microglial
Apoe expression, thereby mitigating ApoE-Ab binding and detri-
mental reduction of Ab phagocytosis. Importantly, our data are
consistentwith recent results showing that forced Il10expression
in brains of APP transgenic mice leads to increased Ab accu-
mulation and worsening of behavioral deficits (Chakrabarty
et al., 2015). Therefore, modulating IL-10 signaling alters the
microglial activation footprint and Ab phagocytosis. Collectively,
these results suggest that rebalancing cerebral innate immunity
and promoting beneficial neuroinflammation may be more
efficacious than generalized anti-inflammatory therapy for AD.EXPERIMENTAL PROCEDURES
Please see Supplemental Experimental Procedures for detailed methods on
immunochemistry, primary microglia isolation, flow cytometry, cell culture,transfection and viral infection, live cell imaging, Ab uptake quantitation,
western blots, ELISA and MSD technology, RNAseq and qPCR, and behav-
ioral experiments.
Human Brain Samples
Frozen human brain tissue used for western blotting was obtained from the
Alzheimer’s Disease Research Center (ADRC, NIA AG05142) Neuropathology
Core (three female and five male AD patient hippocampal samples, 51–100
years old, and four female and two male control hippocampal samples,
74–93 years old). For IHC, paraffin-embedded 10-mm-thick sections from
the HC of six AD patients (three females and three males, 84–87 years old)
and three age-matched non-demented control subjects were obtained from
Dr. Serguei Bannykh, director of the Department of Neuropathology at
Cedars-Sinai Medical Center.
Animals
Tg(APPswe,PSEN1DE9) transgenic mice (referred to as APP/PS1 in this report;
B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax MMRRC, stock #034832) (Jan-
kowsky et al., 2004) were bred with Il10 knockout mice (Ku¨hn et al., 1993)
(B6.129P2-Il10tm1Cgn/J, stock #002251). Both mouse strains are on the
C57BL/6 background and were obtained from the Jackson Laboratory. All
mice were housed under standard conditions with free access to food and
water, and all animal experiments were approved by the University of Southern
California Institutional Animal Care and Use Committee and performed in strict
accordance with National Institutes of Health guidelines and recommenda-
tions from the Association for Assessment and Accreditation of Laboratory
Animal Care International.
Tissue Handling
Mice were perfused with ice-cold PBS and brains were extracted and quar-
tered according to our previously published methods (Tan et al., 2002; Town
et al., 2008). The anterior two quarters were snap-frozen and posterior quarters
were fixed in 4% paraformaldehyde overnight for subsequent agarose or
paraffin embedding.
3D Reconstruction of Confocal Images
Confocal image stacks (acquired at 603 magnification) of amyloid deposits-
associated microglia were converted to 3D images with the surface-rendering
feature of Imaris BitPlane software (version 7.6.1).
RNAseq Gene Expression Analysis
Strand-specific libraries were generated with 1 mg of input RNA using the
TruSeq Stranded mRNA Sample Prep Kit (Illumina) on an Illumnia HiSeq
2000. Gene classes were generated with Cluster3 by applying k means
clustering to mean-centered log2(RPKM) expression values (de Hoon et al.,
2004). Classification of a gene as immune-related was based on KEGG
pathway annotation (www.genome.jp/kegg).
Behavioral Analyses
Behavioral experiments were conducted with age-matched littermates from
12 to 13 months of age, inclusive of the following six genotypes: Il10+/+,
Il10+/, Il10/, APP/PS1+Il10+/+, APP/PS1+Il10+/, or APP/PS1+Il10/. All
experiments were done blind with respect to the genotype of the mice. After
neurological screening, behavioral tests were conducted in increasing order
of difficulty and stress ranging from open field testing, novel object recognition,
the Y-maze task, and the Barnes maze. For each test independently, mice that
did not perform the exercise were excluded from the analysis.
Statistical Analysis
GraphPad Prism software, version 6.0, was used for all statistics. Multiple
group comparisons were performed by one-way analysis of variance fol-
lowed by Dunnett’s, Sidak’s, or Fisher’s LSD post hoc tests. Otherwise,
Student’s t test was performed. For each behavioral test, possible gender
differences within each group were statistically evaluated by analysis of vari-
ance, followed by Sidak’s multiple comparison test. In all cases, p % 0.05
was considered to be statistically significant. All data are presented as
means ± SEM.Neuron 85, 534–548, February 4, 2015 ª2015 Elsevier Inc. 545
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